PharmARC SMMA Case Study on Aricept 23 mg - Public Citizen Petition
by PharmARC
- 3,331 views
In this new era of patients, caregivers, physicians, pharmacists, companies and others expressing and sharing their thoughts and opinions, it is imperative to understand their perceptions on therapy ...
In this new era of patients, caregivers, physicians, pharmacists, companies and others expressing and sharing their thoughts and opinions, it is imperative to understand their perceptions on therapy areas and various treatment options. Typically, triggers generate series of discussions and comments. In this case, Public Citizen Petition to FDA to ban the 23 mg dose of Aricept has been the trigger. The news generated some buzz on social media platforms, blogs, forums and news websites. The discussions were around various issues concerning efficacy, side effects and cost concerns for Aricept 23 mg.
Accessibility
Categories
Upload Details
Uploaded via SlideShare as Microsoft PowerPoint
Usage Rights
© All Rights Reserved
Statistics
- Likes
- 0
- Downloads
- 18
- Comments
- 0
- Embed Views
- Views on SlideShare
- 1,916
- Total Views
- 3,331